Physician profile
Ivette Eunice Suber
NPI 1265401665
$1,664.54
in general payments reported to CMS, 2019-2025
25 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $13.59 · 2021: $449 · 2022: $348 · 2023: $166 · 2024: $161 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.43 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.33 | 2019-2022 | |
| Hologic Sales and Service, LLC | $275.40 | 2021-2025 | Aptima |
| Mayne Pharma Commercial LLC | $180.26 | 2021-2025 | |
| Biotissue Holdings INC. | $150.86 | 2022 | |
| Roche Diagnostics Corporation | $72.12 | 2019 | |
| Shield Therapeutics INC | $64.52 | 2023-2025 | Accrufer |
| Pfizer INC. | $63.59 | 2021-2023 | |
| Agile Therapeutics, INC. | $57.77 | 2021 | |
| Astellas Pharma US INC | $55.47 | 2021-2022 | |
| Organon LLC | $51.88 | 2022-2023 | Nexplanon |
| Therapeuticsmd, INC. | $47.47 | 2021-2022 | |
| Avion Pharmaceuticals | $45.65 | 2020-2023 | Balcoltra |
| Millicent US INC | $44.75 | 2024-2025 | Intrarosa, Femring |
| Coopersurgical, INC. | $43.08 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Evofem Biosciences, INC. | $30.48 | 2021-2025 | Solosec, Phexx, Phexxi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $27.43 | 2019 | |
| Allergan, INC. | $25.20 | 2019 | |
| Acessa Health INC. | $22.31 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.15 | 2025 | Exparel |
| Biogen, INC. | $17.38 | 2025 | Zurzuvae |
| Ethicon US, LLC | $15.21 | 2019 | |
| Merck Sharp & Dohme LLC | $14.48 | 2021 | |
| Exeltis, USA INC. | $14.17 | 2021 | |
| Minerva Surgical, INC | $12.30 | 2019 | |
| Meditrina | $4.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivette Suber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.